TTC19

Across TCGA pan-cancer cohorts, TTC19 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of TTC19’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where TTC19 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types TTC19 is over-expressed in tumor, although a few such as HNSC and CCRCC show the opposite, repressed pattern.

HNSC, CCRCC, and COAD are the cancer types where TTC19 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TTC19 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	−0.459	<.001	11	view →
CCRCC	Female	III,IV	−0.368	<.001	10	view →
COAD	All	II,III,IV	+0.159	<.001	8	view →
LSCC	Male	II,III,IV	−0.331	<.001	7	view →
PDAC	All	All	−0.421	.001	5	view →
LUAD	Male	All	−0.205	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

TTC19–HNSC

Open the HNSC breakdown →